Vitamin K2 inhibits the proliferation of HepG2 cells by up-regulating the transcription of p21 gene

Hepatology Research

Volumn 37, Issue 5, 2007, Pages 360-365

  Liu, Weidong ^a   Nakamura, Hideji ^a   Yamamoto, Teruhisa ^a   Ikeda, Naoto ^a   Saito, Masaki ^a   Ohno, Masao ^a   Hara, Naoki ^a   Imanishi, Hiroyasu ^a   Shimomura, Soji ^a   Yamamoto, Tetsuo ^a   Sakai, Toshiyuki ^b   Nishiguchi, Shuhei ^a   Hada, Toshikazu ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; HepG2; p21; Vitamin K2

Indexed keywords

FARNOQUINONE; LUCIFERASE; PROTEIN P21; PROTEIN P27; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING;

EID: 34247249939     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00058.x     Document Type: Article

References (20)

1. Chlebowski RT, Akman SA, Block JB. Vitamin K in the treatment of cancer. Cancer Treat Rev 1985; 12: 49-63.
2. Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 1990; 75: 1753-62.
3. Wang Z, Wang M, Finn F et al. The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology 1995; 22: 876-82.
4. Hitomi M, Nonomura T, Yokoyama F et al. In vitro and in vivo antitumor effects of vitamin K5 on hepatocellular carcinoma. Int J Oncol 2005; 26: 1337-44.
5. Otsuka M, Kato N, Shao RX et al. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004; 40: 243-51.
6. Markovits J, Wang Z, Carr BI et al. Differential effects of two growth inhibitory K vitamin analogs on cell cycle regulating proteins in human hepatoma cells. Life Sci 2003; 72: 2769-84.
7. Hitomi M, Yokoyama F, Kita Y et al. Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo. Int J Oncol 2005; 26: 713-20.
8. Habu D, Shiomi S, Tamori A et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292: 358-61.
9. El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
10. Minami S, Ohtani-Fujita N, Igata E et al. Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett 1997; 411: 1-6.
11. Koga H, Sakisaka S, Harada M et al. Involvement of p21 (WAF1/Cip1), p27(Kip1), and p18 (INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 2001; 33: 1087-97.
12. Harper JW, Adami GR, Wei N et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
13. Nakano K, Mizuno T, Sowa Y et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 1997; 272: 22199-206.
14. Sowa Y, Orita T, Minamikawa S et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997; 241: 142-50.
15. Inoue T, Kamiyama J, Sakai T. Sp1 and NF-Y synergistically mediate the effect of vitamin D (3) in the p27 (Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 1999; 274: 32309-17.
16. Cheng J, Imanishi H, Liu W et al. Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines. Cancer Sci 2004; 95: 666-73.
17. Kuriyama S, Hitomi M, Yoshiji H et al. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int J Oncol 2005; 27: 505-11.
18. Zenmyo M, Komiya S, Hamada T et al. Transcriptional activation of p21 by vitamin D (3) or vitamin K (2) leads to differentiation of p53-deficient MG-63 osteosarcoma cells. Hum Pathol 2001; 32: 410-16.
19. Fukushima K, Ueno Y, Yamagiwa Y et al. C orrelation between p21 (waf1) and p16 (INK4a) expression in hepatocellular carcinoma. Hepatol Res 2001; 20: 52-67.
20. Omotehara F, Kawamata H, Uchida D et al. Vesnarinone, a differentiation inducing drug, directly activates p21 (waf1) gene promoter via Sp1 sites in a human salivary gland cancer cell line. Br J Cancer 2002; 87: 1042-6.